13F Holdings
中文EN

RPID RAPID MICRO BIOSYSTEMS, INC.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1380106 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.1%
TTM net income YoY-16.1%
TTM EPS YoY-11.0%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-141.5%
Net margin-145.6%
FCF margin-114.8%
EBITDA margin-133.0%

Returns

ROE-141.6%
ROA-76.4%
ROIC (approx.)-135.2%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets69.6%
Debt / equity1.08x
Current ratio2.55x
Interest coverage-21.16x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$33.59M$28.05M$22.52M$17.13M$23.23M
R&D expense$13.60M$14.60M$12.82M$12.87M$9.78M
SG&A expense$22.75M$21.95M$24.94M$26.82M$17.89M
Operating income-$47.39M-$49.92M-$56.56M-$63.22M-$47.23M
Interest expense$1.09M$40,000——$2.65M
Pretax income-$47.08M-$46.87M-$52.44M-$61.38M-$73.43M
Income tax$40,000$22,000$31,000-$576,000$91,000
Net income-$47.12M-$46.89M-$52.47M-$60.81M-$73.52M
EBITDA-$44.14M-$46.56M-$53.46M-$60.38M-$45.70M
EPS (basic)-1.05-1.08-1.22-1.43-3.94
EPS (diluted)-1.05-1.08-1.22-1.43-3.94
Weighted avg. shares (diluted)44.68M43.58M43.02M42.45M19.78M
Banking
Net interest income——$4.21M$1.78M-$2.61M
Balance sheet
Cash & equivalents$20.03M$17.28M$24.57M$27.35M$178.67M
Short-term investments$18.27M$33.82M$67.77M$81.58M$15.11M
Receivables$3.13M$7.52M$5.53M$5.37M$5.00M
Inventory$17.59M$20.20M$19.96M$21.19M$15.67M
Current assets$61.17M$80.92M$120.42M$138.58M$218.12M
PP&E, net$8.97M$11.19M$12.83M$13.82M$11.30M
Total assets$74.85M$98.17M$143.45M$190.65M$241.17M
Current liabilities$18.49M$17.57M$18.99M$19.05M$18.17M
Long-term debt$18.90M$0—$0$0
Total debt$18.90M$0—$0$0
Total liabilities$41.65M$22.82M$25.46M$26.48M$20.19M
Shareholders' equity$33.21M$75.35M$117.99M$164.17M$220.98M
Net debt-$1.13M-$17.28M—-$27.35M-$178.67M
Cash flow statement
Operating cash flow-$31.06M-$44.15M-$45.08M-$58.55M-$54.96M
Capital expenditure$850,000$1.36M$1.84M$6.74M$3.22M
Free cash flow-$31.91M-$45.52M-$46.93M-$65.29M-$58.18M
Investing cash flow$14.33M$36.66M$42.15M-$93.47M-$13.29M
Financing cash flow$19.77M$203,000$149,000$693,000$216.75M
Depreciation & amortization$3.25M$3.36M$3.10M$2.84M$1.53M
Stock-based compensation$4.03M$3.87M$4.75M$4.02M$1.84M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.